Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million

Reuters2025-12-23

Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million

Fulgent Genetics has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a pathology laboratory based in Alpharetta, GA, and to acquire StrataDx, a dermatopathology laboratory located in Lexington, MA, for a total combined purchase price of approximately $55.5 million, to be paid from cash on hand. The proposed acquisitions are expected to add new anatomic pathology services, proprietary PCR tests, and a national client base to Fulgent’s laboratory services platform. The transaction is anticipated to close during the first half of 2026, pending satisfaction of customary closing conditions. According to Ted Hull, CEO of Bako and StrataDx, the collaboration will bring together advanced technology, digital capabilities, and specialized expertise to enhance diagnostic solutions and the client experience.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222736495) on December 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593616458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593616458","market":"fut","top_or_hot":-1,"title":"Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a pathology laboratory based in Alpharetta, GA, and to acquire StrataDx, a dermatopathology laboratory located in Lexington, MA, for a total combined purchase price of approximately $55.5 million, to be paid from cash on hand. The proposed acquisitions are expected to add new anatomic pathology services, proprietary PCR tests, and a national client base to Fulgent’s laboratory services platform. The transaction is anticipated to close during the first half of 2026, pending satisfaction of customary closing conditions. According to Ted Hull, CEO of Bako and StrataDx, the collaboration will bring together advanced technology, digital capabilities, and specialized expertise to enhance diagnostic solutions and the client experience.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222736495) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 05:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a pathology laboratory based in Alpharetta, GA, and to acquire StrataDx, a dermatopathology laboratory located in Lexington, MA, for a total combined purchase price of approximately $55.5 million, to be paid from cash on hand. The proposed acquisitions are expected to add new anatomic pathology services, proprietary PCR tests, and a national client base to Fulgent’s laboratory services platform. The transaction is anticipated to close during the first half of 2026, pending satisfaction of customary closing conditions. According to Ted Hull, CEO of Bako and StrataDx, the collaboration will bring together advanced technology, digital capabilities, and specialized expertise to enhance diagnostic solutions and the client experience.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222736495) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL5fxBwQ:1","article_id":"2593616458","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593616458","pubTimestamp":1766437819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulgent Genetics has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a pathology laboratory based in Alpharetta, GA, and to acquire StrataDx, a dermatopathology laboratory located in Lexington, MA, for a total combined purchase price of approximately $55.5 million, to be paid from cash on hand. The proposed acquisitions are expected to add new anatomic pathology services, proprietary PCR tests, and a national client base to Fulgent’s laboratory services platform. The transaction is anticipated to close during the first half of 2026, pending satisfaction of customary closing conditions. According to Ted Hull, CEO of Bako and StrataDx, the collaboration will bring together advanced technology, digital capabilities, and specialized expertise to enhance diagnostic solutions and the client experience.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","FLGT":"Fulgent Genetics Inc."},"translate_title":"Fulgent Genetics将以5550万美元收购Bako Diagnostics和StrataDx","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":0.9},"content_text":"Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million\n    \n\n        Fulgent Genetics has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, a pathology laboratory based in Alpharetta, GA, and to acquire StrataDx, a dermatopathology laboratory located in Lexington, MA, for a total combined purchase price of approximately $55.5 million, to be paid from cash on hand. The proposed acquisitions are expected to add new anatomic pathology services, proprietary PCR tests, and a national client base to Fulgent’s laboratory services platform. The transaction is anticipated to close during the first half of 2026, pending satisfaction of customary closing conditions. According to Ted Hull, CEO of Bako and StrataDx, the collaboration will bring together advanced technology, digital capabilities, and specialized expertise to enhance diagnostic solutions and the client experience.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251222736495) on December 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593616458","isCrawlerRequest":true}